Table 5.
Scoring System for Post-HSCT Outcome in AML and ALL
| Outcome by Disease | Score | No. of Patients |
|---|---|---|
| AML | ||
| Disease group | ||
| PIF or duration of first CR > 6 months | 0 | 763 |
| Duration of first CR < 6 months | 1 | 374 |
| Cytogenetics prior to HSCT | ||
| Good or intermediate | 0 | 901 |
| Poor | 1 | 236 |
| HLA match group | ||
| HLA identical sibling or well matched or partially matched unrelated | 0 | 900 |
| Mismatched unrelated | 1 | 156 |
| Related other than HLA identical sibling | 2 | 81 |
| Circulating blasts | ||
| Absent | 0 | 503 |
| Present | 1 | 634 |
| Karnofsky or Lansky score | ||
| 90-100 | 0 | 604 |
| < 90 | 1 | 533 |
| ALL | ||
| Disease group | ||
| PIF or first untreated relapse | 0 | 172 |
| First refractory relapse | 1 | 206 |
| Second and additional relapse | 2 | 92 |
| Donor CMV | ||
| Negative | 0 | 235 |
| Positive | 1 | 235 |
| Bone marrow blasts, % | ||
| < 25 | 0 | 268 |
| > 25 | 1 | 202 |
| Age, years | ||
| 1-9 | 0 | 45 |
| 10-39 | 1 | 302 |
| > 40 | 2 | 123 |
NOTE. Overall score is defined as the sum of the scores for each risk factor. For AML, four risk groups were defined as follows: score of 0, 1, 2, and ≥ 3. For ALL, three risks groups were defined as follows: score of 0 or 1; 2; and ≥ 3.
Abbreviations: HSCT, hematopoietic stem-cell transplantation; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; PIF, primary induction failure; CR, complete remission; CMV, cytomegalovirus.